Comparative real-world outcomes of bispecific antibodies versus pomalidomide-based regimens in relapsed/refractory multiple myeloma: A propensity-matched cohort analysis
Analyses show bispecific antibodies yield similar survival but higher hospitalization and neurotoxicity risks in relapsed/refractory multiple myeloma patients.
Key Points
Bispecific antibodies are associated with increased hospitalization risks compared to pomalidomide.
Neurotoxicity occurred more frequently with bispecific antibodies, raising clinical concerns about patient management.
Retrospective propensity-matched cohort analysis assessed outcomes in adults with relapsed/refractory multiple myeloma.
Further research is needed to explore immune dysregulation and effective treatment sequencing strategies.